ES2566973T3 - Uso de SNS-595 para tratar leucemia - Google Patents

Uso de SNS-595 para tratar leucemia Download PDF

Info

Publication number
ES2566973T3
ES2566973T3 ES10177951.0T ES10177951T ES2566973T3 ES 2566973 T3 ES2566973 T3 ES 2566973T3 ES 10177951 T ES10177951 T ES 10177951T ES 2566973 T3 ES2566973 T3 ES 2566973T3
Authority
ES
Spain
Prior art keywords
sns
compound
treat leukemia
obs
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10177951.0T
Other languages
English (en)
Other versions
ES2566973T9 (es
Inventor
Daniel C. Adelman
Jeffrey A. Silverman
Higaki Masaru
Nakao Satoshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Viracta Therapeutics Inc
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sunesis Pharmaceuticals Inc filed Critical Sumitomo Dainippon Pharma Co Ltd
Application granted granted Critical
Publication of ES2566973T3 publication Critical patent/ES2566973T3/es
Publication of ES2566973T9 publication Critical patent/ES2566973T9/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24S—SOLAR HEAT COLLECTORS; SOLAR HEAT SYSTEMS
    • F24S10/00—Solar heat collectors using working fluids
    • F24S10/70—Solar heat collectors using working fluids the working fluids being conveyed through tubular absorbing conduits
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24S—SOLAR HEAT COLLECTORS; SOLAR HEAT SYSTEMS
    • F24S50/00—Arrangements for controlling solar heat collectors
    • F24S50/40—Arrangements for controlling solar heat collectors responsive to temperature
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F24—HEATING; RANGES; VENTILATING
    • F24S—SOLAR HEAT COLLECTORS; SOLAR HEAT SYSTEMS
    • F24S80/00—Details, accessories or component parts of solar heat collectors not provided for in groups F24S10/00-F24S70/00
    • F24S80/60—Thermal insulation
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L31/00—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
    • H01L31/04—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof adapted as photovoltaic [PV] conversion devices
    • H01L31/052—Cooling means directly associated or integrated with the PV cell, e.g. integrated Peltier elements for active cooling or heat sinks directly associated with the PV cells
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L31/00—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
    • H01L31/04—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof adapted as photovoltaic [PV] conversion devices
    • H01L31/054—Optical elements directly associated or integrated with the PV cell, e.g. light-reflecting means or light-concentrating means
    • H01L31/0547—Optical elements directly associated or integrated with the PV cell, e.g. light-reflecting means or light-concentrating means comprising light concentrating means of the reflecting type, e.g. parabolic mirrors, concentrators using total internal reflection
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02S—GENERATION OF ELECTRIC POWER BY CONVERSION OF INFRARED RADIATION, VISIBLE LIGHT OR ULTRAVIOLET LIGHT, e.g. USING PHOTOVOLTAIC [PV] MODULES
    • H02S40/00—Components or accessories in combination with PV modules, not provided for in groups H02S10/00 - H02S30/00
    • H02S40/30—Electrical components
    • H02S40/38—Energy storage means, e.g. batteries, structurally associated with PV modules
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02S—GENERATION OF ELECTRIC POWER BY CONVERSION OF INFRARED RADIATION, VISIBLE LIGHT OR ULTRAVIOLET LIGHT, e.g. USING PHOTOVOLTAIC [PV] MODULES
    • H02S40/00—Components or accessories in combination with PV modules, not provided for in groups H02S10/00 - H02S30/00
    • H02S40/40—Thermal components
    • H02S40/44—Means to utilise heat energy, e.g. hybrid systems producing warm water and electricity at the same time
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/40—Solar thermal energy, e.g. solar towers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/40—Solar thermal energy, e.g. solar towers
    • Y02E10/44—Heat exchange systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/50—Photovoltaic [PV] energy
    • Y02E10/52—PV systems with concentrators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/60—Thermal-PV hybrids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E70/00—Other energy conversion or management systems reducing GHG emissions
    • Y02E70/30—Systems combining energy storage with energy generation of non-fossil origin

Abstract

Un compuesto que es ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)- 1,8-naftiridina-3-carboxílico para uso en un método de tratamiento de leucemia en un paciente, en donde el método comprende administrar el compuesto al paciente en una dosis semanal de 60 mg/m2 - 150 mg/m2.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
Composiciones ácidas (< pH 4) proporcionaron el equilibrio apropiado de mayor solubilidad del SNS-595 y propiedades farmacéuticas deseables (por ejemplo, mayor comodidad para el paciente causándole menos irritación en el sitio de administración). Un ejemplo ilustrativo de una composición adecuada comprende: 10 mg de SNS-595 por mL de solución acuosa de sorbitol al 4,5% ajustado a pH 2,5 con ácido metanosulfónico. Un protocolo para preparar dicha
5 solución incluye lo siguiente para preparar una presentación de 100 mg/10 mL: 100 mg de SNS-595 y 450 mg de Dsorbitol se añaden a agua destilada; el volumen se lleva hasta un volumen 10 mL; y el pH de la solución resultante se ajusta a 2,5 con ácido metanosulfónico. La composición resultante también es adecuada para liofilización. La forma liofilizada se reconstituye luego con agua estéril hasta la concentración apropiada antes de su uso.
Ejemplo 2
10 Farmacocinética de SNS-595 en pacientes con cáncer
SNS-595 se administró a pacientes incluidos en hasta seis ciclos. Se define un ciclo como un periodo de tres semanas, administrando SNS-595 el primer día de cada ciclo (día 0), seguido por al menos 21 días de observación. SNS595 se administró a cohortes de al menos 3 pacientes y el escalamiento de la dosis se realizó por cohortes consecutivos. Las dosis de SNS-595 fueron lineales con AUC∞ y sus propiedades farmacocinéticas fueron notablemente
15 constantes entre pacientes de la misma cohorte. La Figura 1 representa las concentraciones en el plasma de SNS595 con relación al tiempo entre los diversos cohortes de pacientes y la Tabla 1 muestra los parámetros farmacocinéticos derivados de ellas.
Tabla 1
Dosis, mg/m2
HL horas CO ng/mL Cmax. ng/mL Última AUC h-1ng/mL AUC INF_ obs h-1ng/mL CL_obs mL/min/ kg Vz_obs L/kg Vss_ obs L/kg MRTINF_obs h
3
16,27 152,25 138,80 750,08 1139,55 1,14 1,55 1,44 21,96
S.D
4,871 82,282 80,568 87,622 263 0,318 0,297 0,277 6,836
6
20,69 379,69 347,00 2400,00 2890,29 0,71 1,98 1,24 29,05
S.D
0,327 243,598 214,96 170,556 245,64 0,153 0,295 0,218 1,15
12
17,81 2888,60 2246,67 5395,53 6329,15 0,76 1,17 1,07 23,67
S.D
3,896 1302,71 1065,145 292,281 181,804 0,126 0,258 0,184 5,021
24
16,14 2884,702 2703,33 11133,03 12655,32 0,83 1,15 1,06 21,65
S.D
2,601 189,877 2573,02 488,453 851,458 0,108 0,124 0,165 5,261
48
21,32 1964,52 2868,00 21098,53 27347,36 0,99 1,57 1,46 28,90
S.D
6,32 189,877 2379,899 9405,346 14372,787 0,618 0,567 0,47 8,91
60
17,63 4797,47 4537,59 28112,17 33616,18 0,83 1,20 1,08 23,71
S.D
4,15 1947,89 1947,89 9127,12 13081,44 0,352 0,37 0,218 6,93
7

Claims (1)

  1. imagen1
ES10177951.0T 2004-03-15 2005-03-14 Uso de SNS-595 para tratar leucemia Active ES2566973T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55357804P 2004-03-15 2004-03-15
US553578P 2004-03-15

Publications (2)

Publication Number Publication Date
ES2566973T3 true ES2566973T3 (es) 2016-04-18
ES2566973T9 ES2566973T9 (es) 2017-01-03

Family

ID=34993432

Family Applications (3)

Application Number Title Priority Date Filing Date
ES05731600T Active ES2358267T3 (es) 2004-03-15 2005-03-14 Composición farmacéutica que comprende sns-595 y sus usos.
ES05732554T Active ES2334802T3 (es) 2004-03-15 2005-03-14 Sns-595 y metodos de uso del mismo.
ES10177951.0T Active ES2566973T3 (es) 2004-03-15 2005-03-14 Uso de SNS-595 para tratar leucemia

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES05731600T Active ES2358267T3 (es) 2004-03-15 2005-03-14 Composición farmacéutica que comprende sns-595 y sus usos.
ES05732554T Active ES2334802T3 (es) 2004-03-15 2005-03-14 Sns-595 y metodos de uso del mismo.

Country Status (24)

Country Link
US (12) US7968565B2 (es)
EP (4) EP1729770B1 (es)
JP (9) JP5096913B2 (es)
KR (1) KR101169825B1 (es)
CN (5) CN103251589B (es)
AT (2) ATE493982T1 (es)
AU (3) AU2005222622B2 (es)
BR (1) BRPI0508700A (es)
CA (3) CA2559650C (es)
CY (2) CY1109741T1 (es)
DE (2) DE602005025738D1 (es)
DK (3) DK1725233T3 (es)
ES (3) ES2358267T3 (es)
HK (1) HK1097196A1 (es)
HU (1) HUE027266T2 (es)
IL (2) IL177946A (es)
MX (2) MX349188B (es)
NO (3) NO338058B1 (es)
NZ (2) NZ549557A (es)
PL (3) PL1729770T3 (es)
PT (2) PT1729770E (es)
SI (2) SI1725233T1 (es)
WO (2) WO2005089756A1 (es)
ZA (1) ZA200607248B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1729770B1 (en) * 2004-03-15 2009-12-16 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
AU2005286965B2 (en) * 2004-09-17 2009-10-22 Senhwa Biosciences, Inc. Quinolone analogs as cell proliferation inhibitors
US7652134B2 (en) * 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
US20070117770A1 (en) * 2005-08-19 2007-05-24 Cylene Pharmaceuticals, Inc. Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
JP5374153B2 (ja) * 2005-09-02 2013-12-25 サネシス ファーマシューティカルズ， インコーポレイテッド 癌の治療のための（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸を使用する方法
AU2006287149B2 (en) * 2005-09-02 2013-05-23 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20090021215A (ko) * 2006-06-12 2009-02-27 선에시스 파마슈티컬스 인코포레이티드 암의 치료를 위한 화합물 및 조성물
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en) * 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
WO2009049030A1 (en) * 2007-10-09 2009-04-16 Triton Biopharma, Llc Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter
AU2014277779B2 (en) * 2007-10-22 2016-05-19 Sunesis Pharmaceuticals, Inc. METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
WO2009054935A1 (en) * 2007-10-22 2009-04-30 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
UA108194C2 (uk) * 2008-12-31 2015-04-10 Спосіб отримання (+)-1,4-дигідро-7-[(3s,4s)-3-метокси-4-(метиламіно)-1-піролідиніл]-4-оксо-1-(2-тіазоліл)-1,8-нафтиридин-3-карбонової кислоти
CN104688732A (zh) 2009-02-27 2015-06-10 逊尼希思制药公司 利用sns-595治疗具有降低的brca2活性的癌症对象的方法
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
ES2624985T3 (es) 2012-02-27 2017-07-18 Agq Technological Corporate S.A. Supervisión y control de condiciones edáficas
CN106986863B (zh) 2012-04-24 2019-12-31 沃泰克斯药物股份有限公司 Dna-pk抑制剂
CN105246883B (zh) 2013-03-12 2017-07-21 沃泰克斯药物股份有限公司 Dna‑pk抑制剂
US20160067182A1 (en) * 2013-04-09 2016-03-10 Merrimack Pharmaceuticals, Inc. Methods and compositions for improving outcomes of liposomal chemotherapy
WO2015000034A1 (en) * 2013-07-02 2015-01-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iii
PL3424920T3 (pl) 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US216316A (en) * 1879-06-10 Improvement in latches
US3021A (en) * 1843-03-30 Stove with elevated ovejst
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
CZ292631B6 (cs) 1994-06-14 2003-11-12 Dainippon Pharmaceutical Co., Ltd. Deriváty pyridonkarboxylové kyseliny, protinádorové a farmakologické prostředky je obsahující
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
DK0966683T3 (da) * 1997-01-13 2003-08-04 Kudos Pharm Ltd Assays, midler, terapi og diagnose vedrørende moduleirng af cellulær DNA-reparationsaktivitet
US20020032216A1 (en) * 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
US6291643B1 (en) 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
US6171857B1 (en) * 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
CA2332179C (en) * 1998-06-30 2011-06-28 Sloan-Kettering Institute For Cancer Research Uses of dna-pk
US6670144B1 (en) * 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
AU760466B2 (en) 1999-02-26 2003-05-15 Johns Hopkins University, The A novel inhibitor of programmed cell death
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6479541B1 (en) * 2000-03-30 2002-11-12 Baxter International Amiodarone-containing parenteral administration
CA2408749A1 (en) * 2000-05-20 2001-11-29 Cancer Research Technology Limited Drug screening systems and assays
US7179912B2 (en) * 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
US6696483B2 (en) 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
CN1473055A (zh) 2000-11-02 2004-02-04 ˹¡-�����ְ�֢�о��� 通过使用hsp90抑制剂提高细胞毒剂效力的方法
WO2003089573A2 (en) * 2002-04-05 2003-10-30 Fishel Richard A Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
AU2004223866A1 (en) * 2003-03-24 2004-10-07 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
EP1729770B1 (en) * 2004-03-15 2009-12-16 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
AU2006287149B2 (en) 2005-09-02 2013-05-23 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20090021215A (ko) 2006-06-12 2009-02-27 선에시스 파마슈티컬스 인코포레이티드 암의 치료를 위한 화합물 및 조성물
WO2008016678A2 (en) 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en) 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
WO2009054935A1 (en) 2007-10-22 2009-04-30 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
UA108194C2 (uk) 2008-12-31 2015-04-10 Спосіб отримання (+)-1,4-дигідро-7-[(3s,4s)-3-метокси-4-(метиламіно)-1-піролідиніл]-4-оксо-1-(2-тіазоліл)-1,8-нафтиридин-3-карбонової кислоти
CN104688732A (zh) 2009-02-27 2015-06-10 逊尼希思制药公司 利用sns-595治疗具有降低的brca2活性的癌症对象的方法
CN101631081B (zh) 2009-08-12 2011-06-08 华为技术有限公司 一种多级交换网
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer

Also Published As

Publication number Publication date
AU2005222622B2 (en) 2011-04-07
EP3053579A1 (en) 2016-08-10
EP2295056A1 (en) 2011-03-16
AU2005222607A1 (en) 2005-09-29
US8822493B2 (en) 2014-09-02
AU2005222607B2 (en) 2010-11-25
MX349188B (es) 2017-07-17
US7829577B2 (en) 2010-11-09
CN1997368A (zh) 2007-07-11
KR101169825B1 (ko) 2012-07-30
CN103251589B (zh) 2015-09-30
US9757363B2 (en) 2017-09-12
US8669270B2 (en) 2014-03-11
NZ549557A (en) 2010-10-29
JP6352863B2 (ja) 2018-07-04
CA2559652A1 (en) 2005-09-29
HUE027266T2 (en) 2016-10-28
AU2011201277B2 (en) 2012-11-29
EP2295056B9 (en) 2016-09-28
JP2011225590A (ja) 2011-11-10
EP1725233A4 (en) 2009-05-20
ES2334802T3 (es) 2010-03-16
CN104324029A (zh) 2015-02-04
PT1725233E (pt) 2011-03-23
US20110312988A1 (en) 2011-12-22
DK2295056T5 (en) 2016-11-28
NO339613B1 (no) 2017-01-16
JP2018119977A (ja) 2018-08-02
ATE451924T1 (de) 2010-01-15
CY1109741T1 (el) 2014-09-10
WO2005089756A1 (en) 2005-09-29
US20180316309A1 (en) 2018-11-01
PL2295056T3 (pl) 2016-07-29
NO338058B1 (no) 2016-07-25
US20160361302A1 (en) 2016-12-15
SI1729770T1 (sl) 2010-02-26
DE602005025738D1 (de) 2011-02-17
US20140378505A1 (en) 2014-12-25
JP2012140442A (ja) 2012-07-26
CA2559652C (en) 2017-02-14
JP2007529524A (ja) 2007-10-25
ZA200607248B (en) 2009-02-25
US20110263524A1 (en) 2011-10-27
DE602005018333D1 (de) 2010-01-28
JP5096913B2 (ja) 2012-12-12
CA2954578A1 (en) 2005-09-29
NZ588060A (en) 2011-09-30
EP1729770A4 (en) 2007-04-11
JP2015227351A (ja) 2015-12-17
CN103251589A (zh) 2013-08-21
EP1725233B1 (en) 2011-01-05
NO20064647L (no) 2006-10-12
EP2295056B1 (en) 2016-01-06
US20060063795A1 (en) 2006-03-23
CA2559650A1 (en) 2005-09-29
IL177946A (en) 2016-10-31
US20130244967A1 (en) 2013-09-19
JP2014148535A (ja) 2014-08-21
HK1097196A1 (en) 2007-06-22
SI1725233T1 (sl) 2011-04-29
ES2358267T3 (es) 2011-05-09
CN101703508A (zh) 2010-05-12
CN1997368B (zh) 2014-10-22
CN103083316A (zh) 2013-05-08
US7989468B2 (en) 2011-08-02
NO20150466L (no) 2006-10-12
EP1729770B1 (en) 2009-12-16
US20060247267A1 (en) 2006-11-02
JP2015017110A (ja) 2015-01-29
US9980949B2 (en) 2018-05-29
CA2559650C (en) 2013-11-19
US20150190381A1 (en) 2015-07-09
JP2017095471A (ja) 2017-06-01
PL1729770T3 (pl) 2010-05-31
US20060025437A1 (en) 2006-02-02
IL248049A0 (en) 2016-11-30
EP1725233A1 (en) 2006-11-29
MXPA06010382A (es) 2007-04-23
DK1729770T3 (da) 2010-04-12
WO2005089757A1 (en) 2005-09-29
ES2566973T9 (es) 2017-01-03
US20050215583A1 (en) 2005-09-29
CN103083316B (zh) 2015-09-30
DK2295056T3 (en) 2016-04-11
CY1111263T1 (el) 2015-08-05
JP5856644B2 (ja) 2016-02-10
IL177946A0 (en) 2007-03-08
JP2007529528A (ja) 2007-10-25
JP5317472B2 (ja) 2013-10-16
EP1729770A1 (en) 2006-12-13
KR20070033966A (ko) 2007-03-27
ATE493982T1 (de) 2011-01-15
NO20161867A1 (no) 2006-10-12
PT1729770E (pt) 2010-02-08
US20170373636A9 (en) 2017-12-28
AU2011201277A1 (en) 2011-04-07
BRPI0508700A (pt) 2007-08-07
PL1725233T3 (pl) 2011-05-31
DK1725233T3 (da) 2011-03-14
JP6261477B2 (ja) 2018-01-17
US7968565B2 (en) 2011-06-28
AU2005222622A1 (en) 2005-09-29
US20050203120A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
ES2566973T3 (es) Uso de SNS-595 para tratar leucemia
ES2620413T3 (es) Formulaciones veterinarias antihelmínticas tópicas
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
ES2222174T3 (es) Procedimientos y composiciones para aumentar la cifra de leucocitos.
ES2645744T3 (es) Compuestos heterocíclicos, medicamentos que contienen dichos compuestos, uso de los mismos y procedimientos para la preparación de los mismos
BR112020014160A2 (pt) Compostos de benzamida
CY1111159T1 (el) Πυκνα διαλυματα μεθοτρεξατης
ES2383433T3 (es) Formulación farmacéutica de apomorfina para administración bucal
UY28578A1 (es) Derivados de amida
EP1713466B1 (en) Antiparasitic composition containing an organic amine salt of closantel
RU2006130000A (ru) Органические соединения
RU2013121788A (ru) Ингибиторы репликации вич
ES2727454T3 (es) Formulación inyectable
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
RU2008114048A (ru) Комбинации, включающие ингибитор рецептора сэфр (сосудистого эндотелиального фактора роста) и агент, увеличивающий проницаемость
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
DE68901153D1 (de) Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
AR043822A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
US10987338B2 (en) Composition containing artesunate
JP2018530578A (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
BRPI0409380A (pt) composições farmacêuticas
US9611273B2 (en) Trioxane thioacetal monomers and dimers and methods of use thereof